Pfizer, Warner and the Drug Industry's Growth Crisis
In launching its hostile takeover attempt for Warner-Lambert, its most important partner, in order to get 100% of the revenues of Lipitor, Pfizer underlined its own immense growth challenge, and that of the industry at large. Indeed, the growth problem is so serious that Pfizer is reversing what had seemed a highly successful alternative strategy to M&A--it's late-stage co-promotions. Meanwhile, in signing its own deal with American Home, Warner was sending a similar message: its admission of the difficulty of ever finding, through internal research or alliances, a product important enough to replace the earnings of Lipitor.
by Roger Longman
In December 1987, a shoe dropped in the halls of the pharmaceutical industry. Roche 's attempt to take over...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.